Products like ‘Repatha Inj’ & ‘Soolantra Cream 1%’ enter Asan Medical Center

Amgen’s ‘Repatha Inj’ and Galderma’s ‘Soolantra Cream 1%’ entered Asan Medical Center.

At the 142^nd Drug Committee, Asan Medical Center approved introduction of ‘Repatha Inj,’ the Amgen Korea’s PCSK9-inhibiting cholesterol treatment, and ‘Soolantra Cream 1%,’ the Galderma Korea’s local inflammatory lesion treatment. In addition, ‘Fytarex Cap 0.5mg,’ the Sandos Korea’s multiple arteriosclerosis...